



5-1603

1645

#12

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|---|----------------------|----------------------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | Application Number | 10/006,290 |
| | Filing Date | October 22, 2001 |
| | First Named Inventor | Jay WOHLGEMUTH, et al. |
| | Group Art Unit | 1645 |
| | Examiner Name | To Be Assigned |
| Total Number Of Pages In This Submission | 15 + 81 REFS | Attorney Docket No. 506612000100 |

RECEIVED
MAY 19 2003
TECH CENTER 1600/2000

ENCLOSURES (check all that apply)

- | | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers (for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): RETURN RECEIPT POSTCARD |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| | <input type="checkbox"/> Request for Refund | |

SUPPLEMENTAL Information Disclosure Statement - 3 pgs IN DUPL☐ CD, Number of CD(s) _____

PTO-1449 - 4 pgs IN DUPL with [81] references attached



Response to Missing Parts/Incomplete Application



Response to Missing Parts under 37 CFR 1.52 or 1.53

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

| | |
|-------------------------|---|
| Firm or Individual Name | Morrison & Foerster LLP 425 Market Street, San Francisco, CA 94105-2842 Michael R. Ward (Reg. No. 38,651) |
| Signature | <i>Michael R. Ward</i> |
| Date | May 14, 2003 |

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 324 253 838 US

Date of Deposit: May 14, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Commissioner for Patents, MAIL STOP: Art Unit 1645, Alexandria, VA 22313-1450.

EV324253838US

Scott Stewart
SCOTT STEWART



PATENT
Docket No. 506612000100

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 324 253 838 US

Date of Deposit: May 14, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: **Commissioner for Patents, MAIL STOP: Art Unit 1645, Arlexandria, VA 22313-1450.**


SCOTT STEWART

RECEIVED
MAY 19 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Jay WOHLGEMUTH et al.

Serial No.: 10/006,290

Filing Date: October 22, 2001

For: LEUKOCYTE EXPRESSION
PROFILING

Examiner: To Be Assigned

Group Art Unit: 1645

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97

MAIL STOP: Art Unit 1645
Commissioner for Patents
P.O. BOX 1450
Arlington, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☒ **Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.**
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **506612000100**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: May 14, 2003

Respectfully submitted,

By: Michael R. Ward
Michael R. Ward
Registration No. 38,651

Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-6237
Facsimile: (415) 268-7522

Form PTO-1449

Docket Number 506612000100

Application Number 10/006,290

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Jay WOHLGEMUTH et al.

Filing Date October 22, 2001

Group Art Unit 1645

Mailing Date

May 14, 2003

U.S. PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Filing Date If appropriate |
|-------------------|----------|------------|--------------|---------------------|-------|----------|----------------------------|
| | 1. | 4/15/1986 | 4,582,789 | Sheldon, III et al. | | | |
| | 2. | 7/28/1987 | 4,683,195 | Mullis et al. | | | |
| | 3. | 7/28/1987 | 4,683,202 | Mullis | | | |
| | 4. | 12/6/1988 | 4,789,630 | Bloch et al. | | | |
| | 5. | 1/24/1989 | 4,800,159 | Mullis et al. | | | |
| | 6. | 12/26/1989 | 4,889,818 | Gelfand et al. | | | |
| | 7. | 8/7/1990 | 4,946,952 | Kiefer | | | |
| | 8. | 10/23/1990 | 4,965,188 | Mullis et al. | | | |
| | 9. | 11/5/1991 | 5,063,162 | Kiefer | | | |
| | 10. | 11/19/1991 | 5,066,584 | Gyllensten et al. | | | |
| | 11. | 12/24/1991 | 5,075,216 | Innis et al. | | | |
| | 12. | 1/7/1992 | 5,079,352 | Gelfand et al. | | | |
| | 13. | 2/25/1992 | 5,091,310 | Innis | | | |
| | 14. | 8/25/1992 | 5,142,033 | Innis | | | |
| | 15. | 5/11/1993 | 5,210,015 | Gelfand et al. | | | |
| | 16. | 6/15/1993 | 5,219,727 | Wang et al. | | | |
| | 17. | 1/11/1994 | 5,278,043 | Bannwarth et al. | | | |
| | 18. | 5/10/1994 | 5,310,652 | Gelfand et al. | | | |
| | 19. | 5/24/1994 | 5,314,809 | Erlich et al. | | | |
| | 20. | 6/21/1994 | 5,322,770 | Gelfand | | | |
| | 21. | 10/4/1994 | 5,352,600 | Gelfand et al. | | | |
| | 22. | 12/20/1994 | 5,374,553 | Gelfand et al. | | | |
| | 23. | 2/14/1995 | 5,389,512 | Sninsky et al. | | | |
| | 24. | 4/11/1995 | 5,405,774 | Abramson et al. | | | |
| | 25. | 4/18/1995 | 5,407,800 | Gelfand et al. | | | |
| | 26. | 5/2/1995 | 5,411,876 | Bloch et al. | | | |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number **506612000100**Application Number **10/006,290**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Jay WOHLGEMUTH et al.

Filing Date **October 22, 2001**Group Art Unit **1645**

Mailing Date

May 14, 2003

| | | | |
|-----|------------|-----------|------------------|
| 27. | 5/23/1995 | 5,418,149 | Gelfand et al. |
| 28. | 5/30/1995 | 5,420,029 | Gelfand et al. |
| 29. | 10/3/1995 | 5,455,170 | Abramson et al. |
| 30. | 11/14/1995 | 5,466,591 | Abramson et al. |
| 31. | 11/21/1995 | 5,468,613 | Erlich et al. |
| 32. | 12/19/1995 | 5,476,774 | Wang et al. |
| 33. | 1/30/1996 | 5,487,972 | Gelfand et al. |
| 34. | 2/13/1996 | 5,491,063 | Fisher et al. |
| 35. | 2/13/1996 | 5,491,086 | Gelfand et al. |
| 36. | 3/26/1996 | 5,501,963 | Burckhardt |
| 37. | 4/30/1996 | 5,512,462 | Cheng |
| 38. | 7/23/1996 | 5,538,848 | Livak et al. |
| 39. | 10/1/1996 | 5,561,058 | Gelfand et al. |
| 40. | 10/15/1996 | 5,565,339 | Bloch et al. |
| 41. | 11/5/1996 | 5,571,673 | Picone |
| 42. | 11/12/1996 | 5,573,906 | Bannworth et al. |
| 43. | 2/18/1997 | 5,604,099 | Erlich et al. |
| 44. | 4/8/1997 | 5,618,703 | Gelfand et al. |
| 45. | 4/8/1997 | 5,618,711 | Gelfand et al. |
| 46. | 4/29/1997 | 5,624,833 | Gelfand et al. |
| 47. | 6/24/1997 | 5,641,864 | Gelfand |
| 48. | 9/9/1997 | 5,665,551 | Gelfand et al. |
| 49. | 10/7/1997 | 5,674,738 | Abramson et al. |
| 50. | 10/14/1997 | 5,677,152 | Birch et al. |
| 51. | 12/2/1997 | 5,693,517 | Gelfand et al. |
| 52. | 6/30/1998 | 5,773,258 | Birch et al. |
| 53. | 8/4/1998 | 5,789,224 | Gelfand et al. |
| 54. | 8/18/1998 | 5,795,762 | Abramson et al. |
| 55. | 9/8/1998 | 5,804,375 | Gelfand et al. |
| 56. | 8/17/1999 | 5,939,292 | Gelfand et al. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number **506612000100**Application Number **10/006,290**

Applicant

Jay WOHLGEMUTH et al.Filing Date **October 22, 2001**Group Art Unit **1645**

Mailing Date

May 14, 2003

| | | | |
|-----|------------|--------------|----------------|
| 57. | 10/19/1999 | 5,968,799 | Gelfand et al. |
| 58. | 11/30/1999 | 5,994,056 | Higuchi |
| 59. | 12/14/1999 | 6,001,611 | Will |
| 60. | 3/21/2000 | 6,040,166 | Erlich et al. |
| 61. | 10/3/2000 | 6,127,155 | Gelfand et al. |
| 62. | 1/9/2001 | 6,171,785 B1 | Higuchi |
| 63. | 3/6/2001 | 6,197,563 B1 | Erlich et al. |
| 64. | 4/10/2001 | 6,214,979 B1 | Gelfand et al. |
| 65. | 5/8/2001 | 6,228,628 B1 | Gelfand et al. |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Country | Class | Subclass | Translation YES NO |
|----------------------|-------------|------|--------------|---------|-------|----------|-----------------------|
| | | | | | | | |

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

| Examiner Initials | Ref. No. | Title |
|----------------------|-------------|--|
| | 66. | Ajjan, R. A. et al. (1996) "Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis" <i>Clin. Exp. Immunol.</i> 105: 523-528. |
| | 67. | Autieri MV, Kelemen S, Thomas BA, Feller ED, Goldman BI, Eisen HJ. (2002) "Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy" <i>Circulation</i> 106(17):2218-23. |
| | 68. | Baechler, Emily C. et al. (2003) "Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus" <i>Proc. Natl. Acad. Sci. USA</i> 100 (5): 2610-2615. |
| | 69. | Bave, U. (2000) "The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer" <i>J. Immunol.</i> 165: 3519-3526. |
| | 70. | Bave, U. (2001) "Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines" <i>J. Autoimmun.</i> 17: 71-80. |
| | 71. | Creemers P, Brink J, Wainwright H, Moore K, Shephard E, Kahn D. (2002) "Evaluation of peripheral blood CD4 and CD8 lymphocyte subsets, CD69 expression and histologic rejection grade as diagnostic markers for the presence of cardiac allograft rejection" <i>Transpl Immunol.</i> 10(4):285-92. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number **506612000100**Application Number **10/006,290**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Jay WOHLGEMUTH

Filing Date **October 22, 2001**Group Art Unit **1645**

Mailing Date

May 14, 2003

- | | |
|-----|--|
| 72. | Doi, S. et al. (1994) "Polymerase chain reaction quantification of cytokine messenger RNA expression in peripheral blood mononuclear cells of patients with acute exacerbations of asthma: effect of glucocorticoid therapy" <i>Clinical and Experimental Allergy</i> 24: 854-867. |
| 73. | Hooks, J.J. (1979) "Immune interferon in the circulation of patients with autoimmune disease" <i>N. Engl. J. Med.</i> 301: 5-8. |
| 74. | Hooks, J.J. et al. (1982) "Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis" <i>Arthritis Rheum.</i> 25: 396-400. |
| 75. | Magnusson, M. et al. (2001) "Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus-related oligodeoxynucleotide" <i>Scand. J. Immunol.</i> 54: 543-550. |
| 76. | Preble, O.T. (1982) "Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon" <i>Science</i> 216: 429-431. |
| 77. | Schowengerdt et al (2000) "Increased expression of the lymphocyte early activation marker CD69 in peripheral blood correlates with histologic evidence of cardiac allograft rejection." <i>Transplantation</i> 69(10):2102-7 |
| 78. | Shi, S.N. (1987) "Serum interferon in systemic lupus erythematosus" <i>Br. J. Dermatol.</i> 117:155-159. |
| 79. | Toogood, Giles J. et al. (1996) "The Immune Response Following Small Bowel Transplantation" <i>Transplantation</i> 62 (6): 851-855. |
| 80. | Vallin, H. (1999) "Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus" <i>J. Immunol.</i> 163: 6306-6313. |
| 81. | Vandevyver, Caroline et al. (1998) "Cytokine mRNA Profile of Myelin Basic Protein Reactive T-Cell Clones in Patients with Multiple Sclerosis" <i>Autoimmunity</i> 28: 77-89. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.